UY35809A - (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos - Google Patents
(aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usosInfo
- Publication number
- UY35809A UY35809A UY0001035809A UY35809A UY35809A UY 35809 A UY35809 A UY 35809A UY 0001035809 A UY0001035809 A UY 0001035809A UY 35809 A UY35809 A UY 35809A UY 35809 A UY35809 A UY 35809A
- Authority
- UY
- Uruguay
- Prior art keywords
- bleeding
- aza
- prophylaxis
- substituted
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente solicitud se refiere nuevas (aza)piridopirazolopirimidinonas e indazolopirimidinonas sustituidas, a los procesos para su preparación, los compuestos para usar solo o en combinaciones en un procedimiento para el tratamiento y/o la profilaxis de las enfermedades, en particular para el tratamiento y/o la profilaxis del sangrado agudo y recurrente en pacientes con o sin trastornos de sangrado hereditarios o adquiridos subyacentes, en el que el sangrado se asocia con una enfermedad o una intervención médica seleccionadas del grupo que consiste de la menorragia, hemorragia postparto, shock hemorrágico, traumatismo, cirugía, trasplante, accidente cerebrovascular, enfermedades del hígado, angioedema hereditario, sangrado nasal y sinovi tis y el daño del cartílago después de la hemartrosis.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13191642 | 2013-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35809A true UY35809A (es) | 2015-05-29 |
Family
ID=49517406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001035809A UY35809A (es) | 2013-11-05 | 2014-10-31 | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
Country Status (29)
Country | Link |
---|---|
US (3) | US9598417B2 (es) |
EP (1) | EP3066100B1 (es) |
JP (1) | JP6431061B2 (es) |
KR (1) | KR102312780B1 (es) |
CN (1) | CN105683194B (es) |
AP (1) | AP2016009175A0 (es) |
AR (1) | AR098292A1 (es) |
AU (1) | AU2014345771B2 (es) |
CA (1) | CA2929378C (es) |
CL (1) | CL2016001076A1 (es) |
CR (1) | CR20160332A (es) |
CU (1) | CU24361B1 (es) |
DO (1) | DOP2016000102A (es) |
EA (1) | EA029373B1 (es) |
ES (1) | ES2732305T3 (es) |
GT (1) | GT201600084A (es) |
HK (1) | HK1223940A1 (es) |
IL (1) | IL244645B (es) |
MA (1) | MA39018A1 (es) |
MX (1) | MX370419B (es) |
PE (1) | PE20160934A1 (es) |
PH (1) | PH12016500828A1 (es) |
SG (1) | SG11201602133RA (es) |
TN (1) | TN2016000161A1 (es) |
TW (1) | TWI657089B (es) |
UA (1) | UA117504C2 (es) |
UY (1) | UY35809A (es) |
WO (1) | WO2015067549A1 (es) |
ZA (1) | ZA201602311B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY35809A (es) | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
US10118930B2 (en) * | 2014-11-03 | 2018-11-06 | Bayer Pharma Aktiengesellschaft | Piperidinylpyrazolopyrimidinones and their use |
WO2016173948A1 (en) * | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Indazolopyrimidinones as fibrinolysis inhibitors |
WO2017007917A1 (en) * | 2015-07-07 | 2017-01-12 | Mast Therapeutics, Inc. | Polyoxyethylene/polyoxypropylene copolymers and fibrinolytic inhibitors, uses thereof and compositions |
EP3318563A1 (en) | 2016-11-07 | 2018-05-09 | Sanofi | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
CN110590673A (zh) * | 2019-09-02 | 2019-12-20 | 南通大学 | 一种4-氯-7-甲基-1h-吲唑及其化学合成方法 |
US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
US11654057B2 (en) | 2020-04-09 | 2023-05-23 | Bio 54, Llc | Devices for bleeding reduction and methods of making and using the same |
WO2022166845A1 (zh) * | 2021-02-05 | 2022-08-11 | 赛诺哈勃药业(成都)有限公司 | 一种纤溶酶抑制剂、其制备方法及应用 |
US20240228511A1 (en) | 2021-06-09 | 2024-07-11 | Eli Lilly And Company | Substituted fused azines as kras g12d inhibitors |
US11642324B1 (en) | 2022-03-01 | 2023-05-09 | Bio 54, Llc | Topical tranexamic acid compositions and methods of use thereof |
TW202404601A (zh) | 2022-04-05 | 2024-02-01 | 加拿大商索科普拉健康與人類科學兩合公司 | 用於選擇性消退血栓性或血栓栓塞性疾病中血栓的凝乳酶抑制劑 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2192559A5 (en) * | 1972-07-17 | 1974-02-08 | Ugine Kuhlmann | Pyrimidino (1,2-b) indazole derivs - inters for dyes and pharmaceuticals, from 3-aminoindazoles and beta-ketone derivs |
WO2006023000A1 (en) | 2004-07-30 | 2006-03-02 | Xanodyne Pharmaceuticals, Inc. | Tranexamic acid formulations |
AR059224A1 (es) * | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
JP5531011B2 (ja) * | 2008-06-06 | 2014-06-25 | サノフイ | TAFIaの阻害剤としての大環状尿素およびスルファミド誘導体 |
WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
JP5711723B2 (ja) | 2009-04-07 | 2015-05-07 | エメリティ・ファーマ・アクチボラグ | 治療剤としてのイソオキサゾール−3(2h)−オン類似体 |
WO2012047156A1 (en) * | 2010-10-04 | 2012-04-12 | Astrazeneca Ab | Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases |
EP2640705A2 (en) * | 2010-11-15 | 2013-09-25 | Katholieke Universiteit Leuven | Novel antiviral compounds |
WO2012082947A1 (en) * | 2010-12-16 | 2012-06-21 | Irm Llc | Compounds and compositions as tgr5 agonists |
CN103370321B (zh) * | 2010-12-16 | 2015-07-29 | 拜耳知识产权有限责任公司 | 取代的嘧啶并[1,2-b]吲唑及其作为PI3K/AKT途径的调节剂的用途 |
UY35809A (es) * | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
WO2016173948A1 (en) * | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Indazolopyrimidinones as fibrinolysis inhibitors |
-
2014
- 2014-10-31 UY UY0001035809A patent/UY35809A/es not_active Application Discontinuation
- 2014-11-03 TW TW103137976A patent/TWI657089B/zh not_active IP Right Cessation
- 2014-11-03 CU CU2016000062A patent/CU24361B1/es unknown
- 2014-11-03 AP AP2016009175A patent/AP2016009175A0/en unknown
- 2014-11-03 UA UAA201605980A patent/UA117504C2/uk unknown
- 2014-11-03 WO PCT/EP2014/073529 patent/WO2015067549A1/en active Application Filing
- 2014-11-03 SG SG11201602133RA patent/SG11201602133RA/en unknown
- 2014-11-03 PE PE2016000586A patent/PE20160934A1/es unknown
- 2014-11-03 CN CN201480060660.7A patent/CN105683194B/zh not_active Expired - Fee Related
- 2014-11-03 ES ES14793523T patent/ES2732305T3/es active Active
- 2014-11-03 CA CA2929378A patent/CA2929378C/en not_active Expired - Fee Related
- 2014-11-03 KR KR1020167014622A patent/KR102312780B1/ko active IP Right Grant
- 2014-11-03 EP EP14793523.3A patent/EP3066100B1/en active Active
- 2014-11-03 MA MA39018A patent/MA39018A1/fr unknown
- 2014-11-03 EA EA201690935A patent/EA029373B1/ru not_active IP Right Cessation
- 2014-11-03 TN TN2016000161A patent/TN2016000161A1/en unknown
- 2014-11-03 JP JP2016527398A patent/JP6431061B2/ja not_active Expired - Fee Related
- 2014-11-03 MX MX2016005969A patent/MX370419B/es active IP Right Grant
- 2014-11-03 AU AU2014345771A patent/AU2014345771B2/en not_active Ceased
- 2014-11-03 CR CR20160332A patent/CR20160332A/es unknown
- 2014-11-04 AR ARP140104130A patent/AR098292A1/es not_active Application Discontinuation
- 2014-11-05 US US14/533,915 patent/US9598417B2/en active Active
-
2016
- 2016-03-17 IL IL244645A patent/IL244645B/en active IP Right Grant
- 2016-04-06 ZA ZA2016/02311A patent/ZA201602311B/en unknown
- 2016-05-04 PH PH12016500828A patent/PH12016500828A1/en unknown
- 2016-05-05 CL CL2016001076A patent/CL2016001076A1/es unknown
- 2016-05-05 DO DO2016000102A patent/DOP2016000102A/es unknown
- 2016-05-05 GT GT201600084A patent/GT201600084A/es unknown
- 2016-10-27 HK HK16112345.9A patent/HK1223940A1/zh not_active IP Right Cessation
-
2017
- 2017-01-26 US US15/416,651 patent/US10098883B2/en active Active
-
2018
- 2018-08-10 US US16/101,250 patent/US10668071B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY35809A (es) | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos | |
CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
CL2019001079A1 (es) | Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina. | |
DOP2019000287A (es) | Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi) | |
ECSP19025350A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
DOP2012000257A (es) | Derivados del acido 1-amino-2-ciclopropiletilboronico | |
ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
PE20170931A1 (es) | Nuevas normalizaciones y dispositivos medicos para la preparacion de plasma rico en plaquetas (prp) o concentrado de medula osea (bmc) solos o combinados con acido hialuronico | |
BR112015020804A2 (pt) | dispositivo fototerapeutico, método e uso | |
UY33047A (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
CO6592044A2 (es) | Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cancer y enfermedadese inmunes | |
CU24603B1 (es) | Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios | |
CO6531414A2 (es) | Aptámeros del inhibidor de la vía del factor tisular y sus usos como tratamiento de trastornos hemorrágicos | |
BR112016021648A2 (pt) | novos compostos | |
CL2019002079A1 (es) | Sales del inhibidor de pim quinasa; útiles en el tratamiento del cáncer. (divisional solicitud 201800611) | |
NI201600176A (es) | Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer. | |
UY36385A (es) | Piperidinilpirazolopirimidinonas y utilización de las mismas | |
UY37622A (es) | Derivados de pirazol como inhibidores de bromodominio de la familia bet y su uso en aplicaciones terapéuticas | |
CU24283B1 (es) | Composiciones farmacéuticas | |
DOP2017000096A (es) | Uso del ácido neridrónico o de su sal para el tratamiento de la osteoartrosis | |
CL2018000336A1 (es) | Composición para el tratamiento de la mucosidad en las branquias de los peces | |
SV2016005282A (es) | Nuevos compuestos | |
AR101944A1 (es) | Dispositivo para la compresión de la arteria renal en la nefrectomía parcial y método para emplear dicho dispositivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20211215 |